Exact Mass: 630.4135

Caldariellaquinone

C39H66O2S2 (630.4504)

A 1-benzothiophene that is 1-benzothiophene-4,7-dione bearing additional methylthio and 3,7,11,15,19,23-hexamethyltetracosyl substituents at positions 5 and 6 respectively. Isolated from Caldariella acidophila.

2,3,23-Triacetylsericic acid

C36H54O9 (630.3768)

2,3,23-Triacetylsericic acid is found in coffee and coffee products. 2,3,23-Triacetylsericic acid is isolated from Quercus ilex (holly oak Isolated from Quercus ilex (holly oak). 2,3,23-Triacetylsericic acid is found in coffee and coffee products and fats and oils.

Ganoderic acid Mb

C36H54O9 (630.3768)

Constituent of cultured mycelium of Ganoderma lucidum (reishi). 3a,15a,22S-Triacetoxy-7a-hydroxylanosta-8,24E-dien-26-oic acid is found in mushrooms. Ganoderic acid Mb is found in mushrooms. Ganoderic acid Mb is a metabolite of Ganoderma lucidum (reishi

Ganoderic acid Mc

C36H54O9 (630.3768)

Ganoderic acid Mc is found in mushrooms. Ganoderic acid Mc is a metabolite of Ganoderma lucidum (reishi Metabolite of Ganoderma lucidum (reishi). Ganoderic acid Mc is found in mushrooms.

4-Methoxycinnamoyloleanolic acid methyl ester

C41H58O5 (630.4284)

4-Methoxycinnamoyloleanolic acid methyl ester is a constituent of Eucalyptus globulus (Tasmanian blue gum). Constituent of Eucalyptus globulus (Tasmanian blue gum).

PA(a-13:0/18:2(9Z,11Z))

C34H63O8P (630.426)

PA(a-13:0/18:2(9Z,11Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(a-13:0/18:2(9Z,11Z)), in particular, consists of one chain of anteisotridecanoic acid at the C-1 position and one chain of (9Z,11Z)-octadecadienoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(i-13:0/18:2(9Z,11Z))

C34H63O8P (630.426)

PA(i-13:0/18:2(9Z,11Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(i-13:0/18:2(9Z,11Z)), in particular, consists of one chain of isotridecanoic acid at the C-1 position and one chain of (9Z,11Z)-octadecadienoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

4-O-Methyl-12-O-tetradecanoylphorbol 13-acetate

C37H58O8 (630.4131)

Chapso

C32H58N2O8S (630.3914)

Dexamethasone palmitate

C38H59FO6 (630.4295)

trans-1,4-Bis[[1-cyclohexyl-3-(4-dimethylamino phenyl)ureido]methyl]cyclohexane

C38H58N6O2 (630.4621)

PA(10:0/20:3(6,8,11)-OH(5))

C33H59O9P (630.3896)

PA(10:0/20:3(6,8,11)-OH(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:3(6,8,11)-OH(5)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 5-hydroxyeicosatetrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:3(6,8,11)-OH(5)/10:0)

C33H59O9P (630.3896)

PA(20:3(6,8,11)-OH(5)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(6,8,11)-OH(5)/10:0), in particular, consists of one chain of one 5-hydroxyeicosatetrienoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(12:0/18:2(10E,12Z)+=O(9))

C33H59O9P (630.3896)

PA(12:0/18:2(10E,12Z)+=O(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/18:2(10E,12Z)+=O(9)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 9-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:2(10E,12Z)+=O(9)/12:0)

C33H59O9P (630.3896)

PA(18:2(10E,12Z)+=O(9)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:2(10E,12Z)+=O(9)/12:0), in particular, consists of one chain of one 9-oxo-octadecadienoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(12:0/18:2(9Z,11E)+=O(13))

C33H59O9P (630.3896)

PA(12:0/18:2(9Z,11E)+=O(13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/18:2(9Z,11E)+=O(13)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 13-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:2(9Z,11E)+=O(13)/12:0)

C33H59O9P (630.3896)

PA(18:2(9Z,11E)+=O(13)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:2(9Z,11E)+=O(13)/12:0), in particular, consists of one chain of one 13-oxo-octadecadienoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(12:0/18:3(10,12,15)-OH(9))

C33H59O9P (630.3896)

PA(12:0/18:3(10,12,15)-OH(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/18:3(10,12,15)-OH(9)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 9-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:3(10,12,15)-OH(9)/12:0)

C33H59O9P (630.3896)

PA(18:3(10,12,15)-OH(9)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(10,12,15)-OH(9)/12:0), in particular, consists of one chain of one 9-hydroxyoctadecatrienoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(12:0/18:3(9,11,15)-OH(13))

C33H59O9P (630.3896)

PA(12:0/18:3(9,11,15)-OH(13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/18:3(9,11,15)-OH(13)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 13-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:3(9,11,15)-OH(13)/12:0)

C33H59O9P (630.3896)

PA(18:3(9,11,15)-OH(13)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(9,11,15)-OH(13)/12:0), in particular, consists of one chain of one 13-hydroxyoctadecatrienoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(i-12:0/18:2(10E,12Z)+=O(9))

C33H59O9P (630.3896)

PA(i-12:0/18:2(10E,12Z)+=O(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/18:2(10E,12Z)+=O(9)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 9-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:2(10E,12Z)+=O(9)/i-12:0)

C33H59O9P (630.3896)

PA(18:2(10E,12Z)+=O(9)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:2(10E,12Z)+=O(9)/i-12:0), in particular, consists of one chain of one 9-oxo-octadecadienoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(i-12:0/18:2(9Z,11E)+=O(13))

C33H59O9P (630.3896)

PA(i-12:0/18:2(9Z,11E)+=O(13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/18:2(9Z,11E)+=O(13)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 13-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:2(9Z,11E)+=O(13)/i-12:0)

C33H59O9P (630.3896)

PA(18:2(9Z,11E)+=O(13)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:2(9Z,11E)+=O(13)/i-12:0), in particular, consists of one chain of one 13-oxo-octadecadienoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(i-12:0/18:3(10,12,15)-OH(9))

C33H59O9P (630.3896)

PA(i-12:0/18:3(10,12,15)-OH(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/18:3(10,12,15)-OH(9)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 9-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:3(10,12,15)-OH(9)/i-12:0)

C33H59O9P (630.3896)

PA(18:3(10,12,15)-OH(9)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(10,12,15)-OH(9)/i-12:0), in particular, consists of one chain of one 9-hydroxyoctadecatrienoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(i-12:0/18:3(9,11,15)-OH(13))

C33H59O9P (630.3896)

PA(i-12:0/18:3(9,11,15)-OH(13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/18:3(9,11,15)-OH(13)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 13-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:3(9,11,15)-OH(13)/i-12:0)

C33H59O9P (630.3896)

PA(18:3(9,11,15)-OH(13)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(9,11,15)-OH(13)/i-12:0), in particular, consists of one chain of one 13-hydroxyoctadecatrienoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

DG(13:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0)

C38H62O7 (630.4495)

DG(13:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(13:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.

DG(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/13:0/0:0)

C38H62O7 (630.4495)

DG(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/13:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/13:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.

DG(13:0/0:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

C38H62O7 (630.4495)

DG(13:0/0:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.

DG(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0/13:0)

C38H62O7 (630.4495)

DG(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0/13:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.

DG(13:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0)

C38H62O7 (630.4495)

DG(13:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(13:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.

DG(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/13:0/0:0)

C38H62O7 (630.4495)

DG(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/13:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/13:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.

DG(13:0/0:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

C38H62O7 (630.4495)

DG(13:0/0:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.

DG(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0/13:0)

C38H62O7 (630.4495)

DG(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0/13:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.

DG(a-13:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0)

C38H62O7 (630.4495)

DG(a-13:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(a-13:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.

DG(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/a-13:0/0:0)

C38H62O7 (630.4495)

DG(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/a-13:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/a-13:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.

DG(a-13:0/0:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

C38H62O7 (630.4495)

DG(a-13:0/0:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.

DG(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0/a-13:0)

C38H62O7 (630.4495)

DG(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0/a-13:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.

DG(a-13:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0)

C38H62O7 (630.4495)

DG(a-13:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(a-13:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.

DG(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/a-13:0/0:0)

C38H62O7 (630.4495)

DG(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/a-13:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/a-13:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.

DG(a-13:0/0:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

C38H62O7 (630.4495)

DG(a-13:0/0:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.

DG(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0/a-13:0)

C38H62O7 (630.4495)

DG(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0/a-13:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.

DG(i-13:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0)

C38H62O7 (630.4495)

DG(i-13:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(i-13:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.

DG(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/i-13:0/0:0)

C38H62O7 (630.4495)

DG(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/i-13:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/i-13:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.

DG(i-13:0/0:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

C38H62O7 (630.4495)

DG(i-13:0/0:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.

DG(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0/i-13:0)

C38H62O7 (630.4495)

DG(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0/i-13:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.

DG(i-13:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0)

C38H62O7 (630.4495)

DG(i-13:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(i-13:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.

DG(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/i-13:0/0:0)

C38H62O7 (630.4495)

DG(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/i-13:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/i-13:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.

DG(i-13:0/0:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

C38H62O7 (630.4495)

DG(i-13:0/0:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.

DG(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0/i-13:0)

C38H62O7 (630.4495)

DG(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0/i-13:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.

(-)-Pleiomutine

C41H50N4O2 (630.3934)

Macrophyllic acid

C40H54O6 (630.392)

Bryoferulic acid

C40H54O6 (630.392)

12-O-(2-Methylbutyryl)phorbol-13-dodecanoate

C37H58O8 (630.4131)

Saniculagenin A

C37H58O8 (630.4131)

cambogin

C40H54O6 (630.392)

21-desethyl-21-cyclobutyl spinosyn D 17-pseudoaglycone

C36H54O9 (630.3768)

fomitoside F

C37H58O8 (630.4131)

A triterpene glycoside that consists of lanost-8,24-dien-21-oic acid substituted at by a alpha-acetyloxy group at position 3 and a beta-D-xylopyranosyl moiety at position 21 via a glycosidic linkage. Isolated from the fruit body of Fomitopsis pinicola, it exhibits inhibitory activity against COX-1 and COX-2.

beauverolide Ka

C37H50N4O5 (630.3781)

3beta-bryoferulic acid|3beta-O-trans-ferulyl-D:C-friedooleana-7,9(11)-diene-29-oic acid|3beta-[(E)-feruloyloxy]-D:C-friedooleane-7,9(11)-dien-29-oic acid

C40H54O6 (630.392)

C38H62O7

C38H62O7 (630.4495)

kurilensoside F

C33H58O11 (630.3979)

C37H58O8

C37H58O8 (630.4131)

Urs-11-en-28-oic acid,13-hydroxy-3-[[(2E)-3-(4-hydroxy-3-methoxyphenyl)-1-oxo-2-propenyl]oxy]-, g-lactone, (3b)- (9CI)

C40H54O6 (630.392)

12-Tigloyl,22-Ac-12-Oleanene-3,26,21,22,24,28-hexol|21-Tigloyl,22-Ac -(3beta,16alpha,21beta,22alpha)-12-Oleanene-3,16,21,22,24,28-hexol

C37H58O8 (630.4131)

(25S,3S)-(+)-12alpha-hydroxy-3alpha-(3-hydroxy-3-methylglutaryloxy)-24-methyllanosta-8,24(31)-dien-26-oic acid

C37H58O8 (630.4131)

Argiopinin IV

C31H54N10O4 (630.4329)

C33H58O11

C33H58O11 (630.3979)

beta-amyrin-3-O-2-O-acetyl-beta-D-glucoside

C38H62O7 (630.4495)

C38H50N2O6

C38H50N2O6 (630.3669)

3-O-(3-O-acetyl)-alpha-L-arabinopyranosyloleanolic acid

C37H58O8 (630.4131)

(3beta)-17-carboxy-28,30-dinoroleana-12,20(29)-dien-3-yl beta-D-glucopyranosiduronic acid 6-methyl ester|(3beta)-3-hydroxy-noroleana-12,20(29)-dien-28-oic acid 3- (beta-D-glucopyranosiduronic acid 6-methyl ester)

C36H54O9 (630.3768)

21-(E)-feruloyloxy-5alpha-cycloart-24-ene-3,23-dione

C40H54O6 (630.392)

3-O-(4-O-acetyl)-alpha-L-arabinopyranosyloleanolic acid

C37H58O8 (630.4131)

diacetyldimethylbartogenate|dimethyl 2alpha,3beta-diacetyl-19alpha-hydroxybartogenate

C36H54O9 (630.3768)

8beta-(4-steraoyloxyisoraleroyloxy)9beta-hydroxycostunolide|8beta-<4-steraoyloxyisoraleroyloxy>9beta-hydroxycostunolide

C38H62O7 (630.4495)

C41H58O5

C41H58O5 (630.4284)

spinosyn delta

C36H54O9 (630.3768)

oligoporin A

C36H54O9 (630.3768)

1,2-dihydro-5beta,21alpha-dihydroxy-21-methyl-6alpha,7alpha-epoxy-9,13,14-ortho-1alpha-(33E-pentadecenoate)-resiniferonol-36-oic acid|kirkinine E

C36H54O9 (630.3768)

19alpha-hydroxy-2alpha,3alpha,24-triacetoxyurs-12-en-28-oic acid

C36H54O9 (630.3768)

Pittobrevigenin

C37H58O8 (630.4131)

21-Tiglooy,16-Ac-12-Oleanene-3,26,21,22,24,28-hexol|21-Tigloyl,16-Ac-(3beta,16alpha,21beta,22alpha)-12-Oleanene-3,16,21,22,24,28-hexol

C37H58O8 (630.4131)

Lys Ile Gln Asp Lys

C27H50N8O9 (630.3701)

Ser Leu Arg Leu Asp

C27H50N8O9 (630.3701)

Pleiomutine

C41H50N4O2 (630.3934)

KIQDK

C27H50N8O9 (630.3701)

PA(13:0/18:2(9Z,12Z))

C34H63O8P (630.426)

PA(14:0/17:2(9Z,12Z))

C34H63O8P (630.426)

PA(14:1(9Z)/17:1(9Z))

C34H63O8P (630.426)

PA(15:1(9Z)/16:1(9Z))

C34H63O8P (630.426)

PA(16:1(9Z)/15:1(9Z))

C34H63O8P (630.426)

PA(17:1(9Z)/14:1(9Z))

C34H63O8P (630.426)

PA(17:2(9Z,12Z)/14:0)

C34H63O8P (630.426)

PA(18:2(9Z,12Z)/13:0)

C34H63O8P (630.426)

PA(P-16:0/16:1(9Z))

C35H67O7P (630.4624)

PA(P-18:0/14:1(9Z))

C35H67O7P (630.4624)

4-Methoxycinnamoyloleanolic acid methyl ester

C41H58O5 (630.4284)

2,3,23-Triacetylsericic acid

C36H54O9 (630.3768)

Ganoderic acid Mb

C36H54O9 (630.3768)

Ganoderic acid Mc

C36H54O9 (630.3768)

PA 31:2

C34H63O8P (630.426)

PA O-32:2

C35H67O7P (630.4624)

3beta,5beta,10beta,14beta-tetrahydroxy-19-norbufa-20,22-dienolide-3-(14-hydroxy-myristate

C37H58O8 (630.4131)

CHAPSO

C32H58N2O8S (630.3914)

Zinc stearate

C36H70O4Zn (630.4565)

Nutrient supplement

Tetradecanoic acid,(1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-9a-(acetyloxy)-1a,1b,4,4a,5,7a,7b,8,9,9a-decahydro-7b-hydroxy-3-(hydroxymethyl)-4a-methoxy-1,1,6,8-tetramethyl-5-oxo-1H-cyclopropa[3,4]benz[1,2-e]azu

C37H58O8 (630.4131)

(11β,16α)-9-Fluoro-11,17-dihydroxy-16-methyl-3,20-dioxopregna-1,4 -dien-21-yl palmitate

C38H59FO6 (630.4295)

hexadecanoate,tin(2+)

C32H62O4Sn (630.367)

Tereticornate A

C40H54O6 (630.392)

Magnesium stearate

C36H70O4Zn (630.4565)

It is used in foods as a binder, emulsifier, anticaking agent, lubricant and release agent, nutrient supplement, defoaming agent and processing aid.

Dexamethasone Palmitate

C38H59FO6 (630.4295)

1-Cyclohexyl-1-[[4-[[cyclohexyl-[[4-(dimethylamino)phenyl]carbamoyl]amino]methyl]cyclohexyl]methyl]-3-[4-(dimethylamino)phenyl]urea

C38H58N6O2 (630.4621)

Oleanoic acid 3-O-glucuronide

C36H54O9-2 (630.3768)

PA(12:0/18:2(10E,12Z)+=O(9))

C33H59O9P (630.3896)

PA(18:2(10E,12Z)+=O(9)/12:0)

C33H59O9P (630.3896)

PA(12:0/18:2(9Z,11E)+=O(13))

C33H59O9P (630.3896)

PA(18:2(9Z,11E)+=O(13)/12:0)

C33H59O9P (630.3896)

PA(i-12:0/18:2(10E,12Z)+=O(9))

C33H59O9P (630.3896)

PA(18:2(10E,12Z)+=O(9)/i-12:0)

C33H59O9P (630.3896)

PA(i-12:0/18:2(9Z,11E)+=O(13))

C33H59O9P (630.3896)

PA(18:2(9Z,11E)+=O(13)/i-12:0)

C33H59O9P (630.3896)

[(2R)-1-decanoyloxy-3-phosphonooxypropan-2-yl] (6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoate

C33H59O9P (630.3896)

[(2R)-2-decanoyloxy-3-phosphonooxypropyl] (6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoate

C33H59O9P (630.3896)

[(2R)-1-dodecanoyloxy-3-phosphonooxypropan-2-yl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate

C33H59O9P (630.3896)

[(2R)-2-dodecanoyloxy-3-phosphonooxypropyl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate

C33H59O9P (630.3896)

[(2R)-1-dodecanoyloxy-3-phosphonooxypropan-2-yl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate

C33H59O9P (630.3896)

[(2R)-2-dodecanoyloxy-3-phosphonooxypropyl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate

C33H59O9P (630.3896)

PA(i-12:0/18:3(10,12,15)-OH(9))

C33H59O9P (630.3896)

PA(18:3(10,12,15)-OH(9)/i-12:0)

C33H59O9P (630.3896)

PA(i-12:0/18:3(9,11,15)-OH(13))

C33H59O9P (630.3896)

PA(18:3(9,11,15)-OH(13)/i-12:0)

C33H59O9P (630.3896)

DG(13:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0)

C38H62O7 (630.4495)

DG(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/13:0/0:0)

C38H62O7 (630.4495)

DG(13:0/0:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

C38H62O7 (630.4495)

DG(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0/13:0)

C38H62O7 (630.4495)

DG(13:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0)

C38H62O7 (630.4495)

DG(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/13:0/0:0)

C38H62O7 (630.4495)

DG(13:0/0:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

C38H62O7 (630.4495)

DG(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0/13:0)

C38H62O7 (630.4495)

DG(a-13:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0)

C38H62O7 (630.4495)

DG(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/a-13:0/0:0)

C38H62O7 (630.4495)

DG(a-13:0/0:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

C38H62O7 (630.4495)

DG(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0/a-13:0)

C38H62O7 (630.4495)

DG(a-13:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0)

C38H62O7 (630.4495)

DG(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/a-13:0/0:0)

C38H62O7 (630.4495)

DG(a-13:0/0:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

C38H62O7 (630.4495)

DG(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0/a-13:0)

C38H62O7 (630.4495)

DG(i-13:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0)

C38H62O7 (630.4495)

DG(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/i-13:0/0:0)

C38H62O7 (630.4495)

DG(i-13:0/0:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

C38H62O7 (630.4495)

DG(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0/i-13:0)

C38H62O7 (630.4495)

DG(i-13:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0)

C38H62O7 (630.4495)

DG(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/i-13:0/0:0)

C38H62O7 (630.4495)

DG(i-13:0/0:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

C38H62O7 (630.4495)

DG(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0/i-13:0)

C38H62O7 (630.4495)

1-[(3S,9S,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-(1-naphthalenyl)urea

C37H50N4O5 (630.3781)

1-[(3S,9R,10R)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-(1-naphthalenyl)urea

C37H50N4O5 (630.3781)

methyl (1S,9R,16S,18R,21S)-6-[(15R,17S,19R)-15-ethyl-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18)-tetraen-17-yl]-2-methyl-2,12-diazahexacyclo[14.2.2.19,12.01,9.03,8.016,21]henicosa-3(8),4,6-triene-18-carboxylate

C41H50N4O2 (630.3934)

NAGlySer 18:4/13:1

C36H58N2O7 (630.4244)

NAGlySer 18:5/13:0

C36H58N2O7 (630.4244)

NAGlySer 16:4/15:1

C36H58N2O7 (630.4244)

NAGlySer 20:5/11:0

C36H58N2O7 (630.4244)

PE-Cer 15:1;2O/16:2;O

C33H63N2O7P (630.4373)

PE-Cer 15:2;2O/16:1;O

C33H63N2O7P (630.4373)

PE-Cer 17:2;2O/14:1;O

C33H63N2O7P (630.4373)

PE-Cer 13:2;2O/18:1;O

C33H63N2O7P (630.4373)

PE-Cer 18:3;2O/13:0;O

C33H63N2O7P (630.4373)

PE-Cer 12:2;2O/19:1;O

C33H63N2O7P (630.4373)

PE-Cer 17:3;2O/14:0;O

C33H63N2O7P (630.4373)

PE-Cer 15:3;2O/16:0;O

C33H63N2O7P (630.4373)

PE-Cer 13:1;2O/18:2;O

C33H63N2O7P (630.4373)

PE-Cer 18:2;2O/13:1;O

C33H63N2O7P (630.4373)

PE-Cer 19:3;2O/12:0;O

C33H63N2O7P (630.4373)

PE-Cer 16:3;2O/15:0;O

C33H63N2O7P (630.4373)

PE-Cer 16:2;2O/15:1;O

C33H63N2O7P (630.4373)

PE-Cer 14:3;2O/17:0;O

C33H63N2O7P (630.4373)

PE-Cer 19:2;2O/12:1;O

C33H63N2O7P (630.4373)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-undecoxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

C33H59O9P (630.3896)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propan-2-yl] undecanoate

C33H59O9P (630.3896)

PMeOH 13:1_17:1

C34H63O8P (630.426)

PMeOH 15:1_15:1

C34H63O8P (630.426)

PMeOH 13:0_17:2

C34H63O8P (630.426)

PEtOH 14:1_15:1

C34H63O8P (630.426)

PEtOH 12:0_17:2

C34H63O8P (630.426)

PMeOH 12:0_18:2

C34H63O8P (630.426)

PMeOH 14:1_16:1

C34H63O8P (630.426)

PMeOH 14:0_16:2

C34H63O8P (630.426)

PEtOH 13:0_16:2

C34H63O8P (630.426)

PEtOH 13:1_16:1

C34H63O8P (630.426)

[1-hexanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (Z)-nonadec-9-enoate

C34H62O10 (630.4343)

[1-pentanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (Z)-icos-11-enoate

C34H62O10 (630.4343)

[1-propanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (Z)-docos-13-enoate

C34H62O10 (630.4343)

[1-octanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (Z)-heptadec-9-enoate

C34H62O10 (630.4343)

[1-nonanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (Z)-hexadec-9-enoate

C34H62O10 (630.4343)

[1-butanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (Z)-henicos-11-enoate

C34H62O10 (630.4343)

[1-heptanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (Z)-octadec-9-enoate

C34H62O10 (630.4343)

[1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-undecanoyloxypropan-2-yl] (Z)-tetradec-9-enoate

C34H62O10 (630.4343)

[1-dodecanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (Z)-tridec-9-enoate

C34H62O10 (630.4343)

[1-decanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (Z)-pentadec-9-enoate

C34H62O10 (630.4343)

(1-pentanoyloxy-3-phosphonooxypropan-2-yl) (15Z,18Z)-hexacosa-15,18-dienoate

C34H63O8P (630.426)

(1-nonanoyloxy-3-phosphonooxypropan-2-yl) (13Z,16Z)-docosa-13,16-dienoate

C34H63O8P (630.426)

(1-heptanoyloxy-3-phosphonooxypropan-2-yl) (13Z,16Z)-tetracosa-13,16-dienoate

C34H63O8P (630.426)

[1-phosphonooxy-3-[(Z)-tetradec-9-enoyl]oxypropan-2-yl] (Z)-heptadec-9-enoate

C34H63O8P (630.426)

(1-phosphonooxy-3-undecanoyloxypropan-2-yl) (11Z,14Z)-icosa-11,14-dienoate

C34H63O8P (630.426)

[1-phosphonooxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (Z)-octadec-9-enoate

C34H63O8P (630.426)

(1-phosphonooxy-3-tetradecanoyloxypropan-2-yl) (9Z,12Z)-heptadeca-9,12-dienoate

C34H63O8P (630.426)

(1-phosphonooxy-3-tridecanoyloxypropan-2-yl) (9Z,12Z)-octadeca-9,12-dienoate

C34H63O8P (630.426)

[1-[(Z)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (Z)-hexadec-9-enoate

C34H63O8P (630.426)

(1-pentadecanoyloxy-3-phosphonooxypropan-2-yl) (9Z,12Z)-hexadeca-9,12-dienoate

C34H63O8P (630.426)

(1-decanoyloxy-3-phosphonooxypropan-2-yl) (11Z,14Z)-henicosa-11,14-dienoate

C34H63O8P (630.426)

(1-dodecanoyloxy-3-phosphonooxypropan-2-yl) (9Z,12Z)-nonadeca-9,12-dienoate

C34H63O8P (630.426)

[(2R)-3-phosphonooxy-2-undecanoyloxypropyl] (11E,14E)-icosa-11,14-dienoate

C34H63O8P (630.426)

[(2R)-1-phosphonooxy-3-undecanoyloxypropan-2-yl] (5E,8E)-icosa-5,8-dienoate

C34H63O8P (630.426)

[(2R)-3-phosphonooxy-2-tridecanoyloxypropyl] (9E,11E)-octadeca-9,11-dienoate

C34H63O8P (630.426)

[(2R)-1-phosphonooxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (E)-heptadec-9-enoate

C34H63O8P (630.426)

[(2R)-1-phosphonooxy-3-undecanoyloxypropan-2-yl] (11E,14E)-icosa-11,14-dienoate

C34H63O8P (630.426)

[(2R)-1-phosphonooxy-3-tridecanoyloxypropan-2-yl] (9E,11E)-octadeca-9,11-dienoate

C34H63O8P (630.426)

[(2R)-2-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropyl] (E)-hexadec-9-enoate

C34H63O8P (630.426)

[1-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-hydroxypropan-2-yl] (4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoate

C41H58O5 (630.4284)

[(2R)-1-phosphonooxy-3-tetradecanoyloxypropan-2-yl] (9E,12E)-heptadeca-9,12-dienoate

C34H63O8P (630.426)

[(2R)-3-phosphonooxy-2-tetradecanoyloxypropyl] (9E,12E)-heptadeca-9,12-dienoate

C34H63O8P (630.426)

[1-carboxy-3-[3-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-2-[(E)-undec-4-enoyl]oxypropoxy]propyl]-trimethylazanium

C37H60NO7+ (630.437)

[(2S)-1-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-undecanoyloxypropan-2-yl] (E)-tetradec-9-enoate

C34H62O10 (630.4343)

[(2R)-1-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-hexadec-7-enoate

C34H63O8P (630.426)

[(2R)-3-phosphonooxy-2-tridecanoyloxypropyl] (9E,12E)-octadeca-9,12-dienoate

C34H63O8P (630.426)

[(2R)-1-phosphonooxy-3-tridecanoyloxypropan-2-yl] (9E,12E)-octadeca-9,12-dienoate

C34H63O8P (630.426)

[(2R)-1-phosphonooxy-3-tridecanoyloxypropan-2-yl] (2E,4E)-octadeca-2,4-dienoate

C34H63O8P (630.426)

[1-carboxy-3-[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(E)-undec-4-enoyl]oxypropoxy]propyl]-trimethylazanium

C37H60NO7+ (630.437)

(1-pentadecanoyloxy-3-phosphonooxypropan-2-yl) (4E,7E)-hexadeca-4,7-dienoate

C34H63O8P (630.426)

[(2R)-3-phosphonooxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (E)-heptadec-9-enoate

C34H63O8P (630.426)

[1-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-hydroxypropan-2-yl] (7E,9E,11E,13E,15E,17E,19E)-docosa-7,9,11,13,15,17,19-heptaenoate

C41H58O5 (630.4284)

[(2R)-1-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (E)-hexadec-9-enoate

C34H63O8P (630.426)

[(2R)-3-phosphonooxy-2-undecanoyloxypropyl] (5E,8E)-icosa-5,8-dienoate

C34H63O8P (630.426)

[(2R)-1-phosphonooxy-3-tridecanoyloxypropan-2-yl] (6E,9E)-octadeca-6,9-dienoate

C34H63O8P (630.426)

[(2R)-2-decanoyloxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (E)-pentadec-9-enoate

C34H62O10 (630.4343)

[(2S)-1-decanoyloxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (E)-pentadec-9-enoate

C34H62O10 (630.4343)

[1-carboxy-3-[3-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-2-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxypropoxy]propyl]-trimethylazanium

C37H60NO7+ (630.437)

[(2S)-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-undecanoyloxypropyl] (E)-tetradec-9-enoate

C34H62O10 (630.4343)

[(2R)-3-phosphonooxy-2-tridecanoyloxypropyl] (6E,9E)-octadeca-6,9-dienoate

C34H63O8P (630.426)

[(2R)-2-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropyl] (E)-hexadec-7-enoate

C34H63O8P (630.426)

[1-carboxy-3-[2-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-3-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxypropoxy]propyl]-trimethylazanium

C37H60NO7+ (630.437)

[(2R)-3-phosphonooxy-2-tridecanoyloxypropyl] (2E,4E)-octadeca-2,4-dienoate

C34H63O8P (630.426)

2-[[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-nonanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C33H61NO8P+ (630.4135)

[1-carboxy-3-[2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-pentanoyloxypropoxy]propyl]-trimethylazanium

C37H60NO7+ (630.437)

2-[[3-heptanoyloxy-2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C33H61NO8P+ (630.4135)

2-[hydroxy-[3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoxy]-2-octanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C34H65NO7P+ (630.4498)

2-[[2-hexanoyloxy-3-[(11Z,14Z,17Z)-icosa-11,14,17-trienoxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C34H65NO7P+ (630.4498)

2-[[2-butanoyloxy-3-[(10Z,13Z,16Z)-docosa-10,13,16-trienoxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C34H65NO7P+ (630.4498)

2-[hydroxy-[2-[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]oxy-3-pentanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C33H61NO8P+ (630.4135)

2-[[2-[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]oxy-3-propanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C33H61NO8P+ (630.4135)

2-[hydroxy-[2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxy-3-octoxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C34H65NO7P+ (630.4498)

2-[[3-[(12Z,15Z,18Z)-hexacosa-12,15,18-trienoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C34H65NO7P+ (630.4498)

2-[[3-decoxy-2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C34H65NO7P+ (630.4498)

2-[[2-decanoyloxy-3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C34H65NO7P+ (630.4498)

2-[[2-acetyloxy-3-[(10Z,13Z,16Z)-tetracosa-10,13,16-trienoxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C34H65NO7P+ (630.4498)

1-tridecanoyl-2-(9Z,12Z-octadecadienoyl)-glycero-3-phosphate

C34H63O8P (630.426)

BisMePA(30:2)

C35H67O7P (630.4624)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

DG 38:11

C41H58O5 (630.4284)

MGDG 10:0_15:1

C34H62O10 (630.4343)

MGDG 11:0_14:1

C34H62O10 (630.4343)

MGDG 25:1

C34H62O10 (630.4343)

MGDG O-25:2;O

C34H62O10 (630.4343)

DGGA 24:1

C33H58O11 (630.3979)

MGGA 25:1

C34H62O10 (630.4343)

PA O-14:0/18:2

C35H67O7P (630.4624)

PA O-14:1/18:1

C35H67O7P (630.4624)

PA O-16:1/16:1

C35H67O7P (630.4624)

PA O-16:2/16:0

C35H67O7P (630.4624)

PA O-18:0/13:3;O

C34H63O8P (630.426)

PA O-18:1/14:1

C35H67O7P (630.4624)

PA O-18:2/14:0

C35H67O7P (630.4624)

PA O-20:2/12:0

C35H67O7P (630.4624)

PA O-22:2/10:0

C35H67O7P (630.4624)

PA O-30:4;O2

C33H59O9P (630.3896)

PA O-31:3;O

C34H63O8P (630.426)

PA P-14:0/18:1

C35H67O7P (630.4624)

PA P-14:0/18:1 or PA O-14:1/18:1

C35H67O7P (630.4624)

PA P-16:0/16:1

C35H67O7P (630.4624)

PA P-16:0/16:1 or PA O-16:1/16:1

C35H67O7P (630.4624)

PA P-16:1/16:0

C35H67O7P (630.4624)

PA P-16:1/16:0 or PA O-16:2/16:0

C35H67O7P (630.4624)

PA P-18:0/12:3;O2

C33H59O9P (630.3896)

PA P-18:0/14:1

C35H67O7P (630.4624)

PA P-18:0/14:1 or PA O-18:1/14:1

C35H67O7P (630.4624)

PA P-18:1/12:2;O2

C33H59O9P (630.3896)

PA P-18:1/14:0

C35H67O7P (630.4624)

PA P-18:1/14:0 or PA O-18:2/14:0

C35H67O7P (630.4624)

PA P-20:0/11:2;O

C34H63O8P (630.426)

PA P-20:1/12:0

C35H67O7P (630.4624)

PA P-20:1/12:0 or PA O-20:2/12:0

C35H67O7P (630.4624)

PA P-22:1/10:0

C35H67O7P (630.4624)

PA P-22:1/10:0 or PA O-22:2/10:0

C35H67O7P (630.4624)

PA P-32:1

C35H67O7P (630.4624)

PA P-32:1 or PA O-32:2

C35H67O7P (630.4624)

PA 18:0/12:3;O

C33H59O9P (630.3896)

PA 22:0/8:3;O

C33H59O9P (630.3896)

PA 22:2/8:1;O

C33H59O9P (630.3896)

PA 30:3;O

C33H59O9P (630.3896)

PA 11:0_20:2

C34H63O8P (630.426)

PA 13:0_18:2

C34H63O8P (630.426)

PA 14:0_17:2

C34H63O8P (630.426)

PA 14:1_17:1

C34H63O8P (630.426)

PA 15:1_16:1

C34H63O8P (630.426)

LPEth 30:2

C35H67O7P (630.4624)

LPM 31:2

C35H67O7P (630.4624)

PEth 28:3;O

C33H59O9P (630.3896)

PEth 29:2

C34H63O8P (630.426)

PM 29:3;O

C33H59O9P (630.3896)

PM 30:2

C34H63O8P (630.426)

CerPE 12:2;O2/19:1;O

C33H63N2O7P (630.4373)

ST 27:0;O6;Hex

C33H58O11 (630.3979)

n-{3-[(2r,5r,8s,11r,14s)-3,6,9,12,15-pentahydroxy-14-[(4-hydroxyphenyl)methyl]-5,11-diisopropyl-8-(2-methylpropyl)-1,4,7,10,13-pentaazacyclopentadeca-1(15),3,6,9,12-pentaen-2-yl]propyl}guanidine

C31H50N8O6 (630.3853)

methyl (1s,2r,4as,6as,6br,8ar,10s,12ar,12br,14bs)-10-{[(2z)-3-(4-methoxyphenyl)prop-2-enoyl]oxy}-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a-carboxylate

C41H58O5 (630.4284)

3,4,5-trihydroxyoxan-2-yl 2-[7-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methylhept-5-enoate

C37H58O8 (630.4131)

(2s,3ar,5as,5bs,9r,13s,14r,16as,16bs)-9-[(1e)-but-1-en-1-yl]-13-hydroxy-4,14-dimethyl-2-{[(2r,3r,4r,5s,6s)-3,4,5-trimethoxy-6-methyloxan-2-yl]oxy}-1h,2h,3h,3ah,5ah,5bh,6h,9h,10h,11h,12h,13h,14h,16ah,16bh-as-indaceno[3,2-d]oxacyclododecane-7,15-dione

C36H54O9 (630.3768)

1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-14-[(2-methylbutanoyl)oxy]-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-13-yl dodecanoate

C37H58O8 (630.4131)

(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl (1s,3r,6s,7s,8r,11s,12s,15r,16r)-6-hydroxy-7,12,16-trimethyl-15-[(2r)-6-methyl-5-methylidene-4-oxoheptan-2-yl]pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecane-7-carboxylate

C37H58O8 (630.4131)

(2s,6r)-6-[(1r,3ar,5ar,7r,9as,11ar)-7-{[(3s)-4-carboxy-3-hydroxy-3-methylbutanoyl]oxy}-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-7-hydroxy-2-methyl-3-methylideneheptanoic acid

C37H58O8 (630.4131)

n-[(2s,3s)-2-[(s)-hydroxy({[(1s)-1-[(3s)-8-hydroxy-1-oxo-3,4-dihydro-2-benzopyran-3-yl]-3-methylbutyl]-c-hydroxycarbonimidoyl})methyl]-5-oxooxolan-3-yl]-13-methyltetradecanimidic acid

C35H54N2O8 (630.388)

(2r,4as,6as,8ar,10s,12as,14as,14br)-10-{[(2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxy}-2,4a,6a,9,9,12a,14a-heptamethyl-1,3,4,5,6,8,8a,10,11,12,14,14b-dodecahydropicene-2-carboxylic acid

C40H54O6 (630.392)

(2z,6r)-6-[(1r,3as,5ar,9as,11r,11ar)-3a,6,6,9a,11a-pentamethyl-7-oxo-11-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-2-methylhept-2-enoic acid

C36H54O9 (630.3768)

6-(3a,6,6,9a,11a-pentamethyl-7-oxo-11-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl)-2-methylhept-2-enoic acid

C36H54O9 (630.3768)

butyl (6r)-6-[(1r,3ar,4s,5ar,7s,9as,11s,11ar)-11-(acetyloxy)-4,7-dihydroxy-3a,6,6,9a,11a-pentamethyl-3,10-dioxo-1h,2h,4h,5h,5ah,7h,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-4-oxoheptanoate

C36H54O9 (630.3768)

(1r,3as,5ar,5br,7ar,9s,11ar,11br,13ar,13br)-3a-[(acetyloxy)methyl]-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-hexadecahydrocyclopenta[a]chrysen-9-yl (2e)-3-(4-hydroxyphenyl)prop-2-enoate

C41H58O5 (630.4284)

2,2'-dihydroxy-1,1'-diisopropyl-4b,4'b,8,8'-tetramethyl-5h,5'h,6h,6'h,7h,7'h,8ah,8'ah,9h,9'h,10h,10'h-[3,3'-biphenanthrene]-8,8'-dicarboxylic acid

C40H54O6 (630.392)

(5-oxo-1,4-dioxacyclononacosan-2-yl)methyl 3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate

C38H62O7 (630.4495)

methyl 10-{[3-(4-methoxyphenyl)prop-2-enoyl]oxy}-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C41H58O5 (630.4284)

5-(acetyloxy)-6-[3,7-bis(acetyloxy)-4-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methylhept-2-enoic acid

C36H54O9 (630.3768)

(2s,3s,4r,5s,6r)-6-(hydroxymethyl)-2-{[(1s,2s,3s,6s,7s,9r,10s,11r,15r,18s,23s)-7-isopropyl-3,6,11,24,24-pentamethyl-19,21-dioxaheptacyclo[16.3.3.0²,¹⁴.0³,¹¹.0⁶,¹⁰.0¹⁵,²⁰.0¹⁵,²³]tetracos-13-en-9-yl]oxy}-5-methoxyoxane-3,4-diol

C37H58O8 (630.4131)

(2r,4as,6as,8ar,10r,12as,14as,14br)-10-{[(2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxy}-2,4a,6a,9,9,12a,14a-heptamethyl-1,3,4,5,6,8,8a,10,11,12,14,14b-dodecahydropicene-2-carboxylic acid

C40H54O6 (630.392)

methyl (1s,2r,4as,6as,6br,8ar,10s,12ar,12br,14bs)-10-{[(2e)-3-(4-methoxyphenyl)prop-2-enoyl]oxy}-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a-carboxylate

C41H58O5 (630.4284)

(1s,6r,14r,15r)-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-14-[(2-methylbutanoyl)oxy]-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-13-yl dodecanoate

C37H58O8 (630.4131)

(2e,5s,6s)-6-[(1r,3s,3ar,4r,5ar,7r,9as,11ar)-3,7-bis(acetyloxy)-4-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-(acetyloxy)-2-methylhept-2-enoic acid

C36H54O9 (630.3768)

[(2s)-5-oxo-1,4-dioxacyclononacosan-2-yl]methyl (2z)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate

C38H62O7 (630.4495)

2,4,5-trihydroxyoxan-3-yl 2-[7-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methylhept-5-enoate

C37H58O8 (630.4131)

(1s,3br,4r,5ar,9as,9bs,10r,11as)-4-(acetyloxy)-1-[(3s,5r)-5-[(1s)-1,2-dihydroxy-2-methylpropyl]-2-hydroxyoxolan-3-yl]-6,6,9a,11a-tetramethyl-7-oxo-1h,2h,3bh,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-10-yl (2r)-2-methylbutanoate

C36H54O9 (630.3768)

[(2s)-5-oxo-1,4-dioxacyclononacosan-2-yl]methyl (2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate

C38H62O7 (630.4495)

n-{2-[hydroxy({[1-(8-hydroxy-1-oxo-3,4-dihydro-2-benzopyran-3-yl)-3-methylbutyl]-c-hydroxycarbonimidoyl})methyl]-5-oxooxolan-3-yl}-13-methyltetradecanimidic acid

C35H54N2O8 (630.388)

(2s,6r)-6-[(1r,3ar,5ar,7s,9as,11ar)-7-{[(3s)-4-carboxy-3-hydroxy-3-methylbutanoyl]oxy}-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-7-hydroxy-2-methyl-3-methylideneheptanoic acid

C37H58O8 (630.4131)

(1s,4s,5r,10s,13s,17s)-4,5,9,9,13,19,20-heptamethyl-23-oxo-24-oxahexacyclo[15.5.2.0¹,¹⁸.0⁴,¹⁷.0⁵,¹⁴.0⁸,¹³]tetracos-15-en-10-yl (2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate

C40H54O6 (630.392)

(1s,4s,5r,8r,10s,13s,14r,17s,18r,19s,20r)-4,5,9,9,13,19,20-heptamethyl-23-oxo-24-oxahexacyclo[15.5.2.0¹,¹⁸.0⁴,¹⁷.0⁵,¹⁴.0⁸,¹³]tetracos-15-en-10-yl (2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate

C40H54O6 (630.392)

5-(acetyloxy)-6-[4,7-bis(acetyloxy)-3-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methylhept-2-enoic acid

C36H54O9 (630.3768)

methyl 10-{[3-(4-methoxyphenyl)prop-2-enoyl]oxy}-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a-carboxylate

C41H58O5 (630.4284)

7-[(4,5-dihydroxy-3-methoxyoxan-2-yl)oxy]-1-(7-hydroxy-6-methylheptan-2-yl)-9a,11a-dimethyl-dodecahydro-1h-cyclopenta[a]phenanthrene-2,3,3b,5a,6-pentol

C33H58O11 (630.3979)

(2e,5s,6r)-6-[(1r,3s,3ar,4r,5ar,7s,9as,11ar)-4,7-bis(acetyloxy)-3-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-(acetyloxy)-2-methylhept-2-enoic acid

C36H54O9 (630.3768)

methyl (4as,6as,6br,8ar,10s,12ar,12br,14bs)-10-{[(2z)-3-(4-methoxyphenyl)prop-2-enoyl]oxy}-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C41H58O5 (630.4284)

(1s,2s,6r,10s,11r,13s,14r,15r)-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-14-[(2-methylbutanoyl)oxy]-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-13-yl dodecanoate

C37H58O8 (630.4131)

n-(3-{3,6,9,12,15-pentahydroxy-14-[(4-hydroxyphenyl)methyl]-5,11-diisopropyl-8-(2-methylpropyl)-1,4,7,10,13-pentaazacyclopentadeca-1(15),3,6,9,12-pentaen-2-yl}propyl)guanidine

C31H50N8O6 (630.3853)

10,11-bis(acetyloxy)-9-[(acetyloxy)methyl]-1-hydroxy-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

C36H54O9 (630.3768)

(4bs,4'bs,8s,8's)-2,2'-dihydroxy-1,1'-diisopropyl-4b,4'b,8,8'-tetramethyl-5h,5'h,6h,6'h,7h,7'h,8ah,8'ah,9h,9'h,10h,10'h-[3,3'-biphenanthrene]-8,8'-dicarboxylic acid

C40H54O6 (630.392)

(2e,5s,6r)-6-[(1s,3s,3as,4r,5as,7r,9as,11ar)-3,7-bis(acetyloxy)-4-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-(acetyloxy)-2-methylhept-2-enoic acid

C36H54O9 (630.3768)

(4bs,4'bs,8s,8's,8ar,8'ar)-2,2'-dihydroxy-1,1'-diisopropyl-4b,4'b,8,8'-tetramethyl-5h,5'h,6h,6'h,7h,7'h,8ah,8'ah,9h,9'h,10h,10'h-[3,3'-biphenanthrene]-8,8'-dicarboxylic acid

C40H54O6 (630.392)

9-(but-1-en-1-yl)-13-hydroxy-4,14-dimethyl-2-[(3,4,5-trimethoxy-6-methyloxan-2-yl)oxy]-1h,2h,3h,3ah,5ah,5bh,6h,9h,10h,11h,12h,13h,14h,16ah,16bh-as-indaceno[3,2-d]oxacyclododecane-7,15-dione

C36H54O9 (630.3768)

6-{7-[(4-carboxy-3-hydroxy-3-methylbutanoyl)oxy]-11-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl}-2-methyl-3-methylideneheptanoic acid

C37H58O8 (630.4131)

butyl 6-[11-(acetyloxy)-4,7-dihydroxy-3a,6,6,9a,11a-pentamethyl-3,10-dioxo-1h,2h,4h,5h,5ah,7h,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-4-oxoheptanoate

C36H54O9 (630.3768)

3a-[(acetyloxy)methyl]-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-hexadecahydrocyclopenta[a]chrysen-9-yl 3-(4-hydroxyphenyl)prop-2-enoate

C41H58O5 (630.4284)

(2s,6r)-6-[(1r,3as,5ar,7r,9as,11s,11ar)-7-{[(3s)-4-carboxy-3-hydroxy-3-methylbutanoyl]oxy}-11-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-3-methylideneheptanoic acid

C37H58O8 (630.4131)

(2r,3r,4s,5r)-2,4,5-trihydroxyoxan-3-yl (2r)-2-[(1r,3ar,5ar,7r,9as,11ar)-7-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methylhept-5-enoate

C37H58O8 (630.4131)

(2e,5s,6s)-6-[(1r,3s,3ar,4r,5ar,7s,9as,11ar)-4,7-bis(acetyloxy)-3-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-(acetyloxy)-2-methylhept-2-enoic acid

C36H54O9 (630.3768)

(1s,2r,6r,10r,11s,13s,14r,15r)-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-14-{[(2r)-2-methylbutanoyl]oxy}-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-13-yl dodecanoate

C37H58O8 (630.4131)

(2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-{[(1r,4s,5s,8r,9r,12s,13s,16s,19r)-19-methoxy-5,9,17,17-tetramethyl-8-[(2r,4e)-6-methylhepta-4,6-dien-2-yl]-18-oxapentacyclo[10.5.2.0¹,¹³.0⁴,¹².0⁵,⁹]nonadec-2-en-16-yl]oxy}oxane-3,4,5-triol

C37H58O8 (630.4131)

3-{4'-ethoxy-3,4,5',9',9',14',18'-heptamethyl-5,15'-dioxo-21'-oxaspiro[oxolane-2,20'-pentacyclo[12.8.0.0¹,¹⁷.0⁴,¹³.0⁵,¹⁰]docosan]-8'-yloxy}-3-oxopropanoic acid

C36H54O9 (630.3768)

3-[(1's,2s,3s,4s,4'r,5's,8'r,10's,13's,14's,17'r,18'r)-4'-ethoxy-3,4,5',9',9',14',18'-heptamethyl-5,15'-dioxo-21'-oxaspiro[oxolane-2,20'-pentacyclo[12.8.0.0¹,¹⁷.0⁴,¹³.0⁵,¹⁰]docosan]-8'-yloxy]-3-oxopropanoic acid

C36H54O9 (630.3768)

10-{[3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxy}-2,4a,6a,9,9,12a,14a-heptamethyl-1,3,4,5,6,8,8a,10,11,12,14,14b-dodecahydropicene-2-carboxylic acid

C40H54O6 (630.392)

(2e,5s,6r)-6-[(1r,3s,3ar,4r,5ar,7s,9as,11ar)-3,7-bis(acetyloxy)-4-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-(acetyloxy)-2-methylhept-2-enoic acid

C36H54O9 (630.3768)

methyl (1s,9s,16s,18r,21r)-6-[(15s,17r,19r)-15-ethyl-1,11-diazapentacyclo[9.6.2.0²,⁷.0⁸,¹⁸.0¹⁵,¹⁹]nonadeca-2,4,6,8(18)-tetraen-17-yl]-2-methyl-2,12-diazahexacyclo[14.2.2.1⁹,¹².0¹,⁹.0³,⁸.0¹⁶,²¹]henicosa-3,5,7-triene-18-carboxylate

C41H50N4O2 (630.3934)

(1r,2r,3r,3as,3bs,5as,6s,7s,9ar,9br,11ar)-7-{[(2s,3r,4s,5r)-4,5-dihydroxy-3-methoxyoxan-2-yl]oxy}-1-[(2r,6s)-7-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-dodecahydro-1h-cyclopenta[a]phenanthrene-2,3,3b,5a,6-pentol

C33H58O11 (630.3979)

(1r,2r,4as,6as,6br,8ar,9s,10s,11r,12ar,12br,14bs)-10,11-bis(acetyloxy)-9-[(acetyloxy)methyl]-1-hydroxy-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

C36H54O9 (630.3768)

(2s,6r)-6-[(1r,3as,5ar,7s,9as,11r,11ar)-7-{[(3s)-4-carboxy-3-hydroxy-3-methylbutanoyl]oxy}-11-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-3-methylideneheptanoic acid

C37H58O8 (630.4131)

(2s,6r)-6-[(1r,3as,5ar,7s,9as,11s,11ar)-7-{[(3s)-4-carboxy-3-hydroxy-3-methylbutanoyl]oxy}-11-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-3-methylideneheptanoic acid

C37H58O8 (630.4131)

4,5,9,9,13,19,20-heptamethyl-23-oxo-24-oxahexacyclo[15.5.2.0¹,¹⁸.0⁴,¹⁷.0⁵,¹⁴.0⁸,¹³]tetracos-15-en-10-yl 3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate

C40H54O6 (630.392)

(4br,4'bs,8r,8's,8ar,8'as)-2,2'-dihydroxy-1,1'-diisopropyl-4b,4'b,8,8'-tetramethyl-5h,5'h,6h,6'h,7h,7'h,8ah,8'ah,9h,9'h,10h,10'h-[3,3'-biphenanthrene]-8,8'-dicarboxylic acid

C40H54O6 (630.392)

(3r,6s,9s,13r)-6-benzyl-3-[(2r)-butan-2-yl]-5,8,11-trihydroxy-9-(1h-indol-3-ylmethyl)-13-[(2s)-octan-2-yl]-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-2-one

C37H50N4O5 (630.3781)

(2e,5r,6r)-6-[(1r,3s,3ar,4r,5ar,7r,9ar,11as)-4,7-bis(acetyloxy)-3-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-(acetyloxy)-2-methylhept-2-enoic acid

C36H54O9 (630.3768)

(2r)-2-[(1r,3s,3ar,5ar,7r,9as,11ar)-3-hydroxy-7-{[(3s)-3-hydroxy-5-methoxy-3-methyl-5-oxopentanoyl]oxy}-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methylhept-5-enoic acid

C37H58O8 (630.4131)

6-{7-[(4-carboxy-3-hydroxy-3-methylbutanoyl)oxy]-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl}-7-hydroxy-2-methyl-3-methylideneheptanoic acid

C37H58O8 (630.4131)

6-benzyl-5,8,11-trihydroxy-9-(1h-indol-3-ylmethyl)-13-(octan-2-yl)-3-(sec-butyl)-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-2-one

C37H50N4O5 (630.3781)

(2e,5s,6s)-6-[(1r,3s,3ar,4r,5ar,7s,9as,11ar)-3,7-bis(acetyloxy)-4-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-(acetyloxy)-2-methylhept-2-enoic acid

C36H54O9 (630.3768)